Key result
Adding metformin to heart failure therapy boosts EF by ~6% and lowers NT-proBNP in non-diabetics.
Why the study?
Heart failure remains a difficult challenge requiring promoting interventions, and metformin has emerged as a promising therapy.
Does adding daily metformin to standard treatment improve cardiac parameters and biomarkers in non-diabetic patients with heart failure and mid-range ejection fraction?
Population
60 newly diagnosed non-diabetic Iraqi patients with heart failure and mid-range ejection fraction
Comparison
Standard HF treatment plus daily metformin (500 mg) vs standard HF treatment alone
Design
Randomized comparative two-arm parallel clinical study
Follow-up
3 months
Authors
Loading...
Supports metformin addition in non-diabetic HFmrEF; extends evidence from diabetic populations to this group.
RCT (n=60)
Randomized
Does adding daily metformin to standard treatment improve cardiac parameters and biomarkers in non-diabetic patients with heart failure and mid-range ejection fraction?
Absolute Event Rate: 6.1% vs 3.2%
p-value: p=0.023
Adding low-dose metformin to standard therapy in non-diabetic patients with heart failure and mid-range ejection fraction significantly improves ejection fraction and reduces NT-proBNP over 3 months.
Fawzi et al. (2023) conducted an RCT in Heart failure with mid-range ejection fraction (n=60). Metformin vs. Standard HF treatment was evaluated on Ejection fraction (EF) (p=0.023). Adding daily metformin to standard heart failure treatment significantly increased ejection fraction (6.1% vs 3.2%, p=0.023) and reduced NT-proBNP at 3 months in non-diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: